Log in to save to my catalogue

Selinexor demonstrates anti-tumor efficacy in paired patient-derived xenograft models and hydrogel-e...

Selinexor demonstrates anti-tumor efficacy in paired patient-derived xenograft models and hydrogel-e...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_3040426175

Selinexor demonstrates anti-tumor efficacy in paired patient-derived xenograft models and hydrogel-embedded histoculture drug sensitivity test of penile cancer

About this item

Full title

Selinexor demonstrates anti-tumor efficacy in paired patient-derived xenograft models and hydrogel-embedded histoculture drug sensitivity test of penile cancer

Publisher

Berlin/Heidelberg: Springer Berlin Heidelberg

Journal title

Journal of cancer research and clinical oncology, 2023-08, Vol.149 (10), p.6931-6941

Language

English

Formats

Publication information

Publisher

Berlin/Heidelberg: Springer Berlin Heidelberg

More information

Scope and Contents

Contents

Background
Penile cancer is a rare malignancy with a poor prognosis, even with various treatment options. Considering the little progress in the study of the pathogenesis and treatment of penile cancer because of the lack of models that mimic the biological properties of the tumor, we have developed a patient-derived xenograft (PDX) model and pa...

Alternative Titles

Full title

Selinexor demonstrates anti-tumor efficacy in paired patient-derived xenograft models and hydrogel-embedded histoculture drug sensitivity test of penile cancer

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_3040426175

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_3040426175

Other Identifiers

ISSN

0171-5216

E-ISSN

1432-1335

DOI

10.1007/s00432-023-04618-0

How to access this item